Skip to main content

Chronic Granulomatous Disease

6
Pipeline Programs
3
Companies
13
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Gene Therapy
1100%
+ 10 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
8 programs
3
1
XELJANZPhase 1/21 trial
Gene Therapy Method for CGDPhase 1Gene Therapy1 trial
Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem CellsPhase 11 trial
gp91 GransPhase 11 trial
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995N/A1 trial
+3 more programs
Active Trials
NCT02116764Completed137Est. Jun 2022
NCT03278912Withdrawn0Est. Sep 2023
NCT03983837Completed3Est. Nov 2025
+7 more trials
Helixmith
HelixmithKorea - Seoul
1 program
1
VM106Phase 1/21 trial
Active Trials
NCT00778882Withdrawn0Est. Oct 2010
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
2 programs
1
Administration of drugPhase 11 trial
Interferon Gamma-1BN/A1 trial
Active Trials
NCT03548818Completed9Est. Jul 2020
NCT02609932Completed20Est. Feb 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Allergy Therapeuticsinterferon-gamma
Allergy Therapeuticsinterferon-gamma
Allergy TherapeuticsNeocate Splash
Allergy TherapeuticsXELJANZ
HelixmithVM106
Allergy Therapeuticsgp91 Grans
Colorado TherapeuticsAdministration of drug
Allergy TherapeuticsPhagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells
Allergy TherapeuticsGene Therapy Method for CGD
Allergy TherapeuticsNatural History of Intestinal Inflammation in People With Primary Immune Dysregulations
Colorado TherapeuticsInterferon Gamma-1B
Allergy TherapeuticsAnalysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Allergy Therapeuticsinterferon-gamma

Clinical Trials (13)

Total enrollment: 897 patients across 13 trials

NCT01147042Allergy Therapeuticsinterferon-gamma

Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease

Start: May 2010Est. completion: Nov 20142 patients
Phase 4Terminated
NCT00001317Allergy Therapeuticsinterferon-gamma

A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood

Start: May 1992Est. completion: Jul 2001100 patients
Phase 4Completed
NCT03983837Allergy TherapeuticsNeocate Splash

Elemental Diet for Treatment of Inflammatory Bowel Disease in Patients With Chronic Granulomatous Disease

Start: Jun 2021Est. completion: Nov 20253 patients
Phase 2Completed
NCT05104723Allergy TherapeuticsXELJANZ

Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

Start: Aug 2022Est. completion: Jan 202720 patients
Phase 1/2Enrolling By Invitation
NCT00778882HelixmithVM106

Gene Therapy for Chronic Granulomatous Disease in Korea

Start: Jan 2007Est. completion: Oct 20100
Phase 1/2Withdrawn
NCT05189925Allergy Therapeuticsgp91 Grans

NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

Start: Jul 2022Est. completion: Jul 202625 patients
Phase 1Recruiting
NCT02609932Colorado TherapeuticsAdministration of drug

Effect of IFN-γ on Innate Immune Cells

Start: Jul 2016Est. completion: Feb 201920 patients
Phase 1Completed
NCT00394316Allergy TherapeuticsPhagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells

Gene Therapy for Chronic Granulomatous Disease

Start: Oct 2006Est. completion: Apr 20143 patients
Phase 1Terminated
NCT00001476Allergy TherapeuticsGene Therapy Method for CGD

Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up

Start: Jun 1995Est. completion: Dec 201014 patients
Phase 1Completed
NCT03278912Allergy TherapeuticsNatural History of Intestinal Inflammation in People With Primary Immune Dysregulations

Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations

Start: Sep 2023Est. completion: Sep 20230
N/AWithdrawn
NCT03548818Colorado TherapeuticsInterferon Gamma-1B

Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease

Start: May 2018Est. completion: Jul 20209 patients
N/ACompleted
NCT02116764Allergy TherapeuticsAnalysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995

Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995

Start: Jun 2014Est. completion: Jun 2022137 patients
N/ACompleted
NCT00604617Allergy Therapeuticsinterferon-gamma

Interferon-Gamma Release Assays in Tuberculosis (TB) - HIV Co-infected Children

Start: Jan 2009Est. completion: Aug 2012564 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 897 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.